File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study
  • Basic View
  • Metadata View
  • XML View
TitleThe efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study
 
AuthorsLeung, KCM2
McMillan, AS2
Wong, MCM2
Leung, WK2
Mok, MY2
Lau, CS1
 
KeywordsHealth-related quality of life
Oral health
Salivary flow rate
Sjögren's syndrome
 
Issue Date2008
 
PublisherSpringer-Verlag London Ltd. The Journal's web site is located at http://link.springer.de/link/service/journals/10067/
 
CitationClinical Rheumatology, 2008, v. 27 n. 4, p. 429-436 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10067-007-0723-x
 
AbstractCevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). Cevimeline has not been evaluated in southern Chinese patients. Furthermore, the effects of cevimeline on health-related quality of life and oral health status are not known. In this randomised, double-blind, placebo-controlled crossover study, patients received cevimeline 30 mg or matched placebo three times per day over 10 weeks followed by a 4-week washout period before treatment crossover. Participants self-completed the following questionnaires: Xerostomia Inventory (XI), the General Oral Health Assessment Index (GOHAI), the Ocular Surface Disease Index (OSDI) and the Medical Outcomes Short Form (SF-36). Clinical assessments included sialometry, examination of the oral cavity for the degree of xerostomia and dental complications of xerostomia. Fifty patients (22 primary SS and 28 secondary SS) were enrolled in the trial. Forty-four patients completed the study. There was a significant improvement in the XI and GOHAI scores as well as the objective rating of xerostomic signs of the oral cavity after treatment with cevimeline. However, there was no improvement in salivary flow rates and dry eye symptoms. SS patients had lower SF-36 scores, but these did not improve after treatment with cevimeline. © Clinical Rheumatology 2007.
 
ISSN0770-3198
2013 Impact Factor: 1.774
2013 SCImago Journal Rankings: 0.862
 
DOIhttp://dx.doi.org/10.1007/s10067-007-0723-x
 
ISI Accession Number IDWOS:000253974600003
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLeung, KCM
 
dc.contributor.authorMcMillan, AS
 
dc.contributor.authorWong, MCM
 
dc.contributor.authorLeung, WK
 
dc.contributor.authorMok, MY
 
dc.contributor.authorLau, CS
 
dc.date.accessioned2010-09-17T10:23:05Z
 
dc.date.available2010-09-17T10:23:05Z
 
dc.date.issued2008
 
dc.description.abstractCevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). Cevimeline has not been evaluated in southern Chinese patients. Furthermore, the effects of cevimeline on health-related quality of life and oral health status are not known. In this randomised, double-blind, placebo-controlled crossover study, patients received cevimeline 30 mg or matched placebo three times per day over 10 weeks followed by a 4-week washout period before treatment crossover. Participants self-completed the following questionnaires: Xerostomia Inventory (XI), the General Oral Health Assessment Index (GOHAI), the Ocular Surface Disease Index (OSDI) and the Medical Outcomes Short Form (SF-36). Clinical assessments included sialometry, examination of the oral cavity for the degree of xerostomia and dental complications of xerostomia. Fifty patients (22 primary SS and 28 secondary SS) were enrolled in the trial. Forty-four patients completed the study. There was a significant improvement in the XI and GOHAI scores as well as the objective rating of xerostomic signs of the oral cavity after treatment with cevimeline. However, there was no improvement in salivary flow rates and dry eye symptoms. SS patients had lower SF-36 scores, but these did not improve after treatment with cevimeline. © Clinical Rheumatology 2007.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationClinical Rheumatology, 2008, v. 27 n. 4, p. 429-436 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10067-007-0723-x
 
dc.identifier.citeulike2751982
 
dc.identifier.doihttp://dx.doi.org/10.1007/s10067-007-0723-x
 
dc.identifier.eissn1434-9949
 
dc.identifier.epage436
 
dc.identifier.hkuros140990
 
dc.identifier.isiWOS:000253974600003
 
dc.identifier.issn0770-3198
2013 Impact Factor: 1.774
2013 SCImago Journal Rankings: 0.862
 
dc.identifier.issue4
 
dc.identifier.pmid17899308
 
dc.identifier.scopuseid_2-s2.0-40949125731
 
dc.identifier.spage429
 
dc.identifier.urihttp://hdl.handle.net/10722/91670
 
dc.identifier.volume27
 
dc.languageeng
 
dc.publisherSpringer-Verlag London Ltd. The Journal's web site is located at http://link.springer.de/link/service/journals/10067/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofClinical Rheumatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAged, 80 and over
 
dc.subject.meshChina
 
dc.subject.meshCross-Over Studies
 
dc.subject.meshDose-Response Relationship, Drug
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshHealth Surveys
 
dc.subject.meshHumans
 
dc.subject.meshMiddle Aged
 
dc.subject.meshMuscarinic Agonists - adverse effects - therapeutic use
 
dc.subject.meshOral Health
 
dc.subject.meshPatient Satisfaction
 
dc.subject.meshQuality of Life
 
dc.subject.meshQuinuclidines - adverse effects - therapeutic use
 
dc.subject.meshSeverity of Illness Index
 
dc.subject.meshSjogren's Syndrome - complications - ethnology
 
dc.subject.meshThiophenes - adverse effects - therapeutic use
 
dc.subject.meshXerostomia - drug therapy - ethnology - etiology
 
dc.subjectHealth-related quality of life
 
dc.subjectOral health
 
dc.subjectSalivary flow rate
 
dc.subjectSjögren's syndrome
 
dc.titleThe efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Leung, KCM</contributor.author>
<contributor.author>McMillan, AS</contributor.author>
<contributor.author>Wong, MCM</contributor.author>
<contributor.author>Leung, WK</contributor.author>
<contributor.author>Mok, MY</contributor.author>
<contributor.author>Lau, CS</contributor.author>
<date.accessioned>2010-09-17T10:23:05Z</date.accessioned>
<date.available>2010-09-17T10:23:05Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Clinical Rheumatology, 2008, v. 27 n. 4, p. 429-436</identifier.citation>
<identifier.issn>0770-3198</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/91670</identifier.uri>
<description.abstract>Cevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sj&#246;gren&apos;s syndrome (SS). Cevimeline has not been evaluated in southern Chinese patients. Furthermore, the effects of cevimeline on health-related quality of life and oral health status are not known. In this randomised, double-blind, placebo-controlled crossover study, patients received cevimeline 30 mg or matched placebo three times per day over 10 weeks followed by a 4-week washout period before treatment crossover. Participants self-completed the following questionnaires: Xerostomia Inventory (XI), the General Oral Health Assessment Index (GOHAI), the Ocular Surface Disease Index (OSDI) and the Medical Outcomes Short Form (SF-36). Clinical assessments included sialometry, examination of the oral cavity for the degree of xerostomia and dental complications of xerostomia. Fifty patients (22 primary SS and 28 secondary SS) were enrolled in the trial. Forty-four patients completed the study. There was a significant improvement in the XI and GOHAI scores as well as the objective rating of xerostomic signs of the oral cavity after treatment with cevimeline. However, there was no improvement in salivary flow rates and dry eye symptoms. SS patients had lower SF-36 scores, but these did not improve after treatment with cevimeline. &#169; Clinical Rheumatology 2007.</description.abstract>
<language>eng</language>
<publisher>Springer-Verlag London Ltd. The Journal&apos;s web site is located at http://link.springer.de/link/service/journals/10067/</publisher>
<relation.ispartof>Clinical Rheumatology</relation.ispartof>
<subject>Health-related quality of life</subject>
<subject>Oral health</subject>
<subject>Salivary flow rate</subject>
<subject>Sj&#246;gren&apos;s syndrome</subject>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Aged, 80 and over</subject.mesh>
<subject.mesh>China</subject.mesh>
<subject.mesh>Cross-Over Studies</subject.mesh>
<subject.mesh>Dose-Response Relationship, Drug</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Health Surveys</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Muscarinic Agonists - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Oral Health</subject.mesh>
<subject.mesh>Patient Satisfaction</subject.mesh>
<subject.mesh>Quality of Life</subject.mesh>
<subject.mesh>Quinuclidines - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Severity of Illness Index</subject.mesh>
<subject.mesh>Sjogren&apos;s Syndrome - complications - ethnology</subject.mesh>
<subject.mesh>Thiophenes - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Xerostomia - drug therapy - ethnology - etiology</subject.mesh>
<title>The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj&#246;gren&apos;s syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/s10067-007-0723-x</identifier.doi>
<identifier.pmid>17899308</identifier.pmid>
<identifier.scopus>eid_2-s2.0-40949125731</identifier.scopus>
<identifier.hkuros>140990</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-40949125731&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>27</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>429</identifier.spage>
<identifier.epage>436</identifier.epage>
<identifier.eissn>1434-9949</identifier.eissn>
<identifier.isi>WOS:000253974600003</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>2751982</identifier.citeulike>
</item>
Author Affiliations
  1. University of Dundee College of Medicine, Dentistry and Nursing
  2. The University of Hong Kong